Tysabri®

Understanding Tysabri®

Tysabri® is a monoclonal antibody that works by blocking immune cells from crossing the blood-brain barrier and the intestinal wall, thereby reducing inflammation and nerve damage in multiple sclerosis (MS) and decreasing gut inflammation in Crohn’s disease. By binding to alpha-4 integrins, Tysabri® prevents immune cells from entering the brain and spinal cord in MS, or the intestines in Crohn’s disease. This targeted action helps reduce inflammation, lessen relapses, and slow disease progression in these conditions.

How Tysabri® Works:

• Prevents immune cells from crossing the blood-brain barrier, reducing MS-related inflammation and nerve damage.
• Blocks immune cell migration into the intestines, decreasing inflammation in Crohn’s disease.
• Helps reduce relapses and slow disease progression in MS and Crohn’s.

FDA Approvals:

• Multiple Sclerosis (MS): Approved on November 23, 2004
• Crohn’s Disease: Approved on January 14, 2008

For more information, please visit the Tysabri® patient website and speak with your healthcare provider to determine if Tysabri® is the right treatment option for you.